210 related articles for article (PubMed ID: 11825001)
1. Hepatitis C virus infection: an overview.
Hwang SJ
J Microbiol Immunol Infect; 2001 Dec; 34(4):227-34. PubMed ID: 11825001
[TBL] [Abstract][Full Text] [Related]
2. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
[TBL] [Abstract][Full Text] [Related]
3. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
4. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection.
Lehmann M; Meyer MF; Monazahian M; Tillmann HL; Manns MP; Wedemeyer H
J Med Virol; 2004 Jul; 73(3):387-91. PubMed ID: 15170633
[TBL] [Abstract][Full Text] [Related]
5. Chronic hepatitis C.
Sherlock DS
Dis Mon; 1994 Mar; 40(3):117-96. PubMed ID: 7513276
[TBL] [Abstract][Full Text] [Related]
6. [Hepatitis C: epidemiology and therapy--with special reference to long-term prognosis after IFN therapy].
Fujiyama S; Tanaka M
Rinsho Byori; 2000 Jan; 48(1):5-13. PubMed ID: 10756668
[TBL] [Abstract][Full Text] [Related]
7. Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy.
Januszkiewicz-Lewandowska D; Wysocki J; Pernak M; Nowicka K; Zawada M; Rembowska J; Lewandowski K; Mańkowski P; Nowak J
Jpn J Infect Dis; 2007 Feb; 60(1):29-32. PubMed ID: 17314422
[TBL] [Abstract][Full Text] [Related]
8. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Chu CM; Sheen IS; Liaw YF
Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
[TBL] [Abstract][Full Text] [Related]
9. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.
Radkowski M; Gallegos-Orozco JF; Jablonska J; Colby TV; Walewska-Zielecka B; Kubicka J; Wilkinson J; Adair D; Rakela J; Laskus T
Hepatology; 2005 Jan; 41(1):106-14. PubMed ID: 15619235
[TBL] [Abstract][Full Text] [Related]
10. Ribavirin in the treatment of hepatitis C.
Abonyi ME; Lakatos PL
Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
[TBL] [Abstract][Full Text] [Related]
11. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis.
Watkins-Riedel T; Ferenci P; Steindl-Munda P; Gschwantler M; Mueller C; Woegerbauer M
Clin Infect Dis; 2004 Dec; 39(12):1754-60. PubMed ID: 15578395
[TBL] [Abstract][Full Text] [Related]
12. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and clinical aspects on hepatitis C.
Higuchi M; Tanaka E; Kiyosawa K
Jpn J Infect Dis; 2002 Jun; 55(3):69-77. PubMed ID: 12195046
[TBL] [Abstract][Full Text] [Related]
14. [Hepatitis C].
Krarup HB; Krogsgaard K
Ugeskr Laeger; 1994 Jul; 156(28):4129-34. PubMed ID: 8066908
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
[TBL] [Abstract][Full Text] [Related]
16. Daily interferon therapy for chronic hepatitis C: a report of a community practice experience.
Srinivas D; Mani H; Crumpler C; Van Thiel DH
Hepatogastroenterology; 2002; 49(46):1053-7. PubMed ID: 12143200
[TBL] [Abstract][Full Text] [Related]
17. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
[TBL] [Abstract][Full Text] [Related]
19. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
